As impressive as it was for the efficacy of recombinant EPO to reduce the transfusion needs of patients with chronic kidney failure, the size of this patient population is not sufficiently great to justify the enormous commercial expansion of the drug. The gene discussed is EPO; the disease is chronic renal failure syndrome.